GLP-1 Agonist Analog Patent - Enzene Biosciences
Summary
The European Patent Office published patent EP3921337A2 for Enzene Biosciences Ltd., covering a glucagon-like peptide-1 (GLP-1) agonist analog, its preparation process, and therapeutic uses. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, and Spain. This patent grant provides Enzene Biosciences with exclusive intellectual property rights for this GLP-1 analog compound in designated territories.
What changed
The European Patent Office granted patent EP3921337A2 to Enzene Biosciences Ltd. for a GLP-1 (glucagon-like peptide-1) agonist analog, covering the molecular compound, its synthesis process, and pharmaceutical applications. The patent is classified under C07K 14/605 (peptides) and A61K 38/26 (pharmaceutical preparations containing peptides), with designated states spanning the majority of European jurisdictions.
For pharmaceutical and biotechnology companies developing GLP-1 based therapeutics for diabetes, obesity, or metabolic disorders, this patent creates potential blocking IP that may require licensing negotiations or design-around strategies. Generic and biosimilar manufacturers should conduct freedom-to-operate analyses, while potential collaboration partners may explore licensing opportunities with Enzene Biosciences.
What to do next
- Monitor patent portfolio for potential licensing opportunities
- Review freedom-to-operate for GLP-1 related products
- Assess blocking risks if developing competing GLP-1 therapeutics
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST ANALOG, PROCESS OF PREPARATION AND USES THEREOF
Publication EP3921337A2 Kind: A2 Apr 01, 2026
Applicants
Enzene Biosciences Ltd.
Inventors
GADGIL, Himanshu, BANERJEE, Abir, LONDHE, Harshita, MAGDUM, Deepali, LEVIN, Daniel, SINGH, Sandeep
IPC Classifications
C07K 14/605 20060101AFI20210817BHEP A61K 38/26 20060101ALI20210817BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.